Literature DB >> 34192971

MiR-296-5p ameliorates deep venous thrombosis by inactivating S100A4.

Zhichang Pan1, Yu Zhang2, Chuanyong Li1, Yuan Yin3, Rui Liu4, Guangfeng Zheng1, Weijian Fan1, Qiang Zhang1, Zhenyu Song1, Ziyue Guo1, Jianjie Rong1, Yixin Shen2.   

Abstract

Deep venous thrombosis is one of the most common venous thromboembolic diseases and has a low cure rate and a high postoperative recurrence rate. Furthermore, emerging evidence indicates that microRNAs are involved in deep venous thrombosis. miR-296-5p is an important microRNA that plays a critical role in various cellular functions, and S100A4 is closely related to vascular function. miR-296-5p is downregulated in deep venous thrombosis patients, and its predicted target S100A4 is upregulated in deep venous thrombosis patients. Therefore, it was hypothesized that miR-296-5p may play a vital role in the development of deep venous thrombosis by targeting S100A4. An Ox-LDL-stimulated HUVEC and deep venous thrombosis mouse model was employed to detect the biological functions of miR-296-5p and S100A4. Dual luciferase reporter assays and pull-down assays were used to authenticate the interaction between miR-296-5p and S100A4. ELISA and Western blotting were employed to detect the protein levels of thrombosis-related factors and the endothelial-to-mesenchymal transition (EndMT)-related factors. The miR-296-5p levels were reduced, while the S100A4 levels were enhanced in deep venous thrombosis patients, and the miR-296-5p levels were negatively correlated with the S100A4 levels in deep venous thrombosis patients. miR-296-5p suppressed S100A4 expression by targeting the 3' UTR of S100A4. MiR-296-5p knockdown accelerated ox-LDL-induced HUVEC apoptosis, oxidative stress, thrombosis-related factor expression, and EndMT, while S100A4 knockdown antagonized these effects in ox-LDL-induced HUVECs. S100A4 knockdown reversed the effect induced by miR-296-5p knockdown. Moreover, the in vivo studies revealed that miR-296-5p knockdown in deep venous thrombosis mice exacerbated deep venous thrombosis formation, whereas S100A4 knockdown had the opposite effect. These results indicate that elevated miR-296-5p inhibits deep venous thrombosis formation by inhibiting S100A4 expression. Both miR-296-5p and S100A4 may be potential diagnostic markers and therapeutic targets for deep venous thrombosis.

Entities:  

Keywords:  Deep venous thrombosis; EndMT; S100A4; miR-296-5p; oxidative stress

Mesh:

Substances:

Year:  2021        PMID: 34192971      PMCID: PMC8581828          DOI: 10.1177/15353702211023034

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  29 in total

Review 1.  Dysregulation of matrix metalloproteinases and their tissue inhibitors by S100A4.

Authors:  Renate Elenjord; Hilde Ljones; Elisabeth Sundkvist; Thrina Loennechen; Jan Olof Winberg
Journal:  Connect Tissue Res       Date:  2008       Impact factor: 3.417

Review 2.  MicroRNAs: important modulators of oxLDL-mediated signaling in atherosclerosis.

Authors:  Erli Zhang; Yongjian Wu
Journal:  J Atheroscler Thromb       Date:  2012-10-13       Impact factor: 4.928

3.  Endothelial Dysfunction and Venous Thrombosis.

Authors:  Pavel Poredos; Mateja K Jezovnik
Journal:  Angiology       Date:  2017-09-27       Impact factor: 3.619

4.  Overcoming Radioresistance in Tumor Therapy by Alleviating Hypoxia and Using HIF-1 Inhibitor.

Authors:  Xingguo Zhou; Hanghang Liu; Yanhui Zheng; Yaobao Han; Tingting Wang; Hao Zhang; Qiao Sun; Zhen Li
Journal:  ACS Appl Mater Interfaces       Date:  2020-01-08       Impact factor: 9.229

5.  S100A4 is expressed at site of invasion in rheumatoid arthritis synovium and modulates production of matrix metalloproteinases.

Authors:  L Senolt; M Grigorian; E Lukanidin; B Simmen; B A Michel; K Pavelka; R E Gay; S Gay; M Neidhart
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

6.  New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis.

Authors:  Isis E Fernandez; Oliver Eickelberg
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

7.  Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.

Authors:  Elisabeth M Zeisberg; Oleg Tarnavski; Michael Zeisberg; Adam L Dorfman; Julie R McMullen; Erika Gustafsson; Anil Chandraker; Xueli Yuan; William T Pu; Anita B Roberts; Eric G Neilson; Mohamed H Sayegh; Seigo Izumo; Raghu Kalluri
Journal:  Nat Med       Date:  2007-07-29       Impact factor: 53.440

Review 8.  Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis.

Authors:  Zhiyun Jiang; Junfen Ma; Qian Wang; Fan Wu; Jiedan Ping; Liang Ming
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 9.  Immune Factors in Deep Vein Thrombosis Initiation.

Authors:  Ivan Budnik; Alexander Brill
Journal:  Trends Immunol       Date:  2018-05-16       Impact factor: 16.687

View more
  1 in total

1.  Suppression of long intergenic non-protein coding RNA 1123 constrains lower extremity deep vein thrombosis via microRNA-125a-3p to target interleukin 1 receptor type 1.

Authors:  Baocai Yang; ZiXiang Zhang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.